Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

AiVita Biomedical

Request full access

Medicine company develops commercial and clinical stage programs utilizing curative and regenerative medicines

Irvine, United StatesFounded 2016Biotech & Life Sciences

About AiVita Biomedical

AIVITA Biomedical is a cutting-edge immuno-oncology company founded in 2016. The company specializes in creating personalized vaccines aimed at targeting the root cause of all cancers, known as tumor-initiating cells. These cells are the seeds from which cancer grows. AIVITA leverages its deep expertise in stem cell growth and precise differentiation to develop safe, efficient, and cost-effective manufacturing processes for cancer therapies and other medical fields.

AIVITA Biomedical primarily serves patients battling various forms of cancer. The company operates in the biotechnology and healthcare markets, focusing on innovative cancer treatments. Their business model revolves around the development and commercialization of personalized cancer vaccines. These vaccines are tailored to each patient's unique tumor profile, aiming to provide a more effective and targeted treatment option.

The company generates revenue through multiple streams. Firstly, it raises funds through financing rounds, such as the recent $12.5 million Series B2 round. Secondly, it sells innovative skincare products that utilize growth factors from skin stem cells. These products are clinically proven to support skin maintenance and renewal. Importantly, all proceeds from skincare sales are directed towards funding ovarian cancer treatments, showcasing the company's commitment to both innovation and social responsibility.

AIVITA Biomedical has also made significant strides in COVID-19 research, with its CEO, Hans Keirstead, being recognized for his contributions. The company is actively involved in clinical trials, including a Phase 2 trial for glioblastoma, a type of brain cancer, demonstrating its ongoing commitment to advancing cancer treatment.

In summary, AIVITA Biomedical is a pioneering company in the field of immuno-oncology, dedicated to developing personalized cancer vaccines and innovative skincare products, with a strong focus on research and social impact.

Source: Dealroom company data

At a glance

Status
Operational
Employees
21
Open positions
2
Dealroom signal
40.7/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Oncology, Skin Care, Wellness and Beauty, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
LATE VCOther financing Sep 2022 $85M $340M Undisclosed ↗
EARLY VCOther financing Aug 2022 $6M $24M Undisclosed ↗
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

AiVita Biomedical website traffic

Latest recorded traffic for AiVita Biomedical is 3K monthly website visits, up 215.8% over the last three months. AiVita Biomedical's team grew 5% over the past year.

Latest monthly visits3K 3-month web change+215.8% 1-year team growth+5%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

AiVita Biomedical in the Irvine ecosystem

Live from Dealroom

The AiVita Biomedical office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • California Institute for Regenerative Medicine

Series A1 investor entered at this stage

  • California Technology Ventures
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 5 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about AiVita Biomedical on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See AiVita Biomedical’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.